Respiratory Disorders Treatment Market

[170+ Pages Research Report] Respiratory Disorders Treatment Market to surpass USD 175.7 billion by 2032 from USD 90.65 billion in 2021 at a CAGR of 6.2% throughout the forecast period 2022-32

Product Overview

Respiratory Disorders are illnesses that impact the lungs and surrounding parts of the respiratory system. Smoking tobacco, second-hand tobacco, asbestos, infection, radon, or other air pollution types are all possible causes of these diseases. COPD, asthma, pneumonia, pulmonary fibrosis, and lung cancer are examples of respiratory ailments. Pills might range from a variety of inhalers to oral medications to intravenous therapies, depending on the respiratory disease. The doctor must discuss the potential advantages and drawbacks of each medicine before prescribing. Using a bronchoscope, interventional bronchoscopy allows for less invasive treatment of lung malignancies as well as respiratory disorders, such as severe asthma and emphysema. For some individuals, lung transplantation is a possibility with serious progressing diseases.

Market Highlights

The Respiratory Disorders Treatment Market is expected to project a notable CAGR of 6.2% in 2032.

Respiratory Disorders Treatment Market to surpass USD 175.7 billion by 2032 from USD 90.65 billion in 2021 at a CAGR of 6.2% in the coming years, i.e., 2022-32. Since the coronavirus directly impacts the respiratory system, research institutions and governments have shifted their efforts to lessen the virus's severity in both existing and new patients, which ultimately has an impact on market growth. Also, continuing R&D initiatives have a great potential for improvements in the Respiratory Disorders Treatment Market.

Figure - Market Analysis of Respiratory Disorders Treatment Market

Get More Information - Download Free Sample

Respiratory Disorders Treatment Market: Segments

The Chronic Obstructive Pulmonary Disease (COPD) segment is expected to grow with a higher CAGR during 2022-32

Respiratory Disorders Treatment Market is categorized on the basis of Disease into Asthma, Chronic Obstructive Pulmonary Disease (COPD), Lung Cancer, Respiratory Tract Infection, Allergic Rhinitis, Cystic Fibrosis (CF), and Others. The Chronic Obstructive Pulmonary Disease (COPD) segment is anticipated to lead the market over the forecast period. COPD is the third most common cause of death followed by asthma. It results in chronic and deteriorating respiratory symptoms, such as coughing, phlegm production, and breathing problems. To stop the progression of symptoms and lessen flare-ups, early diagnosis and treatment are necessary, including assistance for quitting smoking.

The Bronchodilators segment is expected to grow with a higher CAGR during 2022-32

Respiratory Disorders Treatment Market is categorized on the basis of Drug Class into Bronchodilators, Corticosteroids, Combination Drugs, Antibiotics, Target Therapy, Immunotherapy, CFTR, and Others. The bronchodilators segment is more frequently used than others due to the ability to greatly ease breathing by relaxing the lung muscles and opening the airways. Long-Acting and Short-Acting variations of the therapy are also available. Breathlessness attacks that come suddenly and unexpectedly can be temporarily relieved with short-acting. Regular usage of Long-Acting can assist manage asthmatic and COPD dyspnea and improve the efficiency of corticosteroids in the treatment of the condition.

Figure - Market Analysis of Global Respiratory Disorders Treatment Market

Get More Information - Download Free Sample

Market Dynamics

Growth Drivers

Rising Cases of Respiratory Disorders and Innovations in the Drug Development

The Respiratory Disorders Treatment Market will rise due to the widespread usage of leukotriene blocking medications for the treatment of asthma due to their efficacy. Growing lung transplant cases in nations like the U.S. and the UK will support the growth of the market. After lung tissue has been damaged by respiratory illnesses, lung tissue repair and regeneration aid in rebuilding the lungs. Mepolizumab and omalizumab are widely used to treat severe asthma, and this is what is driving the market. This will help the Respiratory Disorders Treatment Market grow in the years to come. During the forecast period, advancements in the development of drugs to treat respiratory problems will boost the market growth.

Widespread Use of Translational Lung Medicines and Rising Pollution Due to Vehicle Emissions

Respiratory Disorders Treatment Market will expand due to the widespread use of translational lung medicine. Increased study of the lung microbiome will help the development of new drugs for the treatment of chronic respiratory illnesses, opening up lucrative new markets for the sector to treat respiratory ailments. The market will grow more rapidly due to the growth in respiratory illnesses owing to the increased pollution from car emissions and the rising use of combination pharmacological therapy. This is projected to drive the Respiratory Disorders Treatment Market over the forecast period.

Restraint

Availability of Generic Medicines and Patent Expiry of Branded Drugs

Patents prevent other producers from creating medicines that are only produced by the patent holder. The pharmaceutical sector is significantly impacted when a branded drug's patent expires. The revenue from the sale of branded medications is hampered by patent expiration, and this has an impact on a company's market share. A few companies in the market for treating respiratory ailments are concerned about patient expiration, which expands the availability of generic medications and increases price pressure on the makers.

Recent Developments

• Boehringer Ingelheim International GmbH invested EUR 105 Mn in April 2019 for the development of respiratory pipeline medicines to expand its production facilities in Germany. The next-generation inhaler Respimat's production capacity in Europe would increase due to this investment and expansion.

• The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave AstraZeneca a favorable recommendation in July 2019 to use Fasenra (benralizumab) in pre-filled, single-use auto-injectors (the Fasenra pen). This made it possible for medical professionals to use biologics to treat a number of people with severe eosinophilic asthma.
• For the treatment of severe eosinophilic asthma in children between the ages of 6 and 11, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline plc's biologic Nucala (mepolizumab) in September 2019. With its approval, patients between the ages of 6 and 11 in the United States can now receive an add-on medication for severe eosinophilic asthma.

Respiratory Disorders Treatment Market: Key Players

• Johnson & Johnson

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Sanofi
• GlaxoSmithKline plc
• Pfizer Inc.
• AstraZeneca plc
• Merck & Co. Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries
• Viatris
• Cipla
• CHIESI Farmaceutici S.p.A.
• Sunovion Pharmaceuticals Inc.
• Avalyn Pharma
• Other Prominent Players

Respiratory Disorders Treatment Market: Regions

Respiratory Disorders Treatment Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America led the market with a higher revenue share in the past years and is expected to lead the market in the future as well. The cost-effectiveness of interventions for chronic obstructive pulmonary diseases and asthma in nations like the U.S. and Canada is responsible for the regional market growth over the projected period. Early risk identification, individual and community involvement, preventive actions, and proactive strategies will also support corporate growth trends. Regional market size is also influenced by the development of improved tools.

Get More Information - Download Free Sample

Impact of Covid-19 on Respiratory Disorders Treatment Market

The global Respiratory Disorders Treatment Market has benefited from the viral proliferation of the coronavirus. The advancements in the detection and treatment of respiratory illnesses are primarily responsible for the sustainability of the market. Although the COVID-19 pandemic has severely damaged businesses worldwide, the demand for treatments for respiratory disorders has increased during the epidemic.

Respiratory Disorders Treatment Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Respiratory Disorders Treatment Market report also contains analysis on:

Respiratory Disorders Treatment Market Segments:

• By Disease 
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Lung Cancer
  • Respiratory Tract Infection
  • Allergic Rhinitis
  • Cystic Fibrosis (CF)
  • Others
• By Route of Administration 
  • Oral
  • Nasal
  • Injectable
• By Drug Class
  • Bronchodilators
  • Corticosteroids
  • Combination Drugs
  • Antibiotics
  • Target Therapy
  • Immunotherapy
  • CFTR
  • Others 
• Respiratory Disorders Treatment Market Dynamics
• Respiratory Disorders Treatment Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies Involved in the Market
• Value Chain of the Market
• Market Drivers and Restraints

Respiratory Disorders Treatment Market Report Scope and Segmentation

Frequently Asked Questions (FAQ):